# Signals Article: Putative Target P62736 for Aortic Stenosis
Background
Aortic stenosis is a common and serious heart valve disease characterized by the narrowing of the aortic valve opening, which restricts blood flow from the heart to the rest of the body. It can lead to significant symptoms and complications, including heart failure. Despite the availability of surgical interventions, there is a need for novel therapeutic targets to improve non-surgical treatment options.
Data-mining rationale
In a recent reanalysis effort, UniProt entry P62736 was identified as a putative target for aortic stenosis. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200199995, GDS:200285666, GDS:200270186, GDS:200226781, and GDS:200233819. Although P62736 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing P62736 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of P62736's potential as a target for aortic stenosis. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of P62736 as a target for aortic stenosis, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of aortic stenosis. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of P62736. If validated, assessing the druggability of P62736 via DGIdb and ChEMBL will be crucial for potential therapeutic development.